Adding ipilimumab to pembrolizumab does not improve efficacy in patients with NSCLC

January 29, 2021

(Singapore Embargoed for 7:23pm EST on January 29, 2021 to coincide with publication in the Journal of Clinical Oncology) -- Adding ipilimumab to pembrolizumab does not improve efficacy and is associated with greater toxicity than pembrolizumab alone as first-line therapy for metastatic non-small cell lung cancer (NSCLC) for patients with a PD-L1 tumor proportion score of greater than or equal to 50% and no targetable EGFR or ALK aberrations, according to research presented today at the International Association for the Study of Lung Cancer's World Conference on Lung Cancer.

The research was presented by Dr. Michael Boyer, clinical professor of medicine at the Chris O'Brien Lifehouse and the Central Clinical School of the University of Sydney, Sydney, Australia.

Previously, the KEYNOTE-024 study showed that pembrolizumab monotherapy significantly improved survival versus platinum-doublet chemotherapy for patients with metastatic NSCLC, a PD-L1 TPS greater than or equal to 50%, and no targetable EGFR or ALK aberrations.

Boyer and his research group, which consisted of centers in Europe, Asia, and North America, conducted the randomized, double-blind, phase III KEYNOTE-598 study (NCT03302234) to determine whether adding ipilimumab to pembrolizumab improved efficacy over pembrolizumab alone in this population.

The trial enrolled 568 participants -- 284 received a combination of pembrolizumab and ipilimumab and 284 were randomly assigned to receive pembrolizumab and placebo.

Patients were randomly assigned 1:1 to ipilimumab at 1 mg/kg every six weeks or to saline placebo for up to 18 cycles. Patients in both arms received 200 mg of pembrolizumab every three weeks for up to 35 cycles. Random assignment was stratified by European Cooperative Oncology Group score of (0 vs 1), region (East Asia vs not East Asia), and histology (squamous vs nonsquamous). Treatment differences in the primary endpoints of overall survival and progress-free survival were assessed by the stratified log-rank test in the intent-to-treat population.

The protocol-specified first interim analysis (IA1) was planned to occur when approximately 255 deaths occurred and approximately 12 months had passed since the last participant was randomly assigned. Nonbinding futility criteria at IA1 were differences in the restricted mean survival time between ipilimumab/pembrolizumab and placebo/pembrolizumab of less than or equal to 0.2 at the maximum observation time and less than or equal to 0.1 at 24 months of follow-up.

With 272 deaths, median overall survival was 21.4 months for patients who received ipilimumab/pembrolizumab compared to 21.9 months for placebo/pembrolizumab (HR, 1.08 ;95% CI: 0.85-1.37; p = 0.74). Restricted mean survival time differences were -0.56 at the maximum observation time and -0.52 at 24 months, which met the futility criteria, according to Dr. Boyer.

With 372 events, median progression-free survival was 8.2 months for the ipilimumab/pembrolizumab group compared with 8.4 months for placebo/pembrolizumab (HR, 1.06; 95% CI: 0.86-1.30; p = 0.72). The objective response rate was 45.4% in both arms; median duration of response was 16.1 months for the ipilimumab/pembrolizumab group vs 17.3 months for placebo/pembrolizumab. Treatment-related adverse events occurred in 76.2% of patients in the ipilimumab/pembrolizumab group versus 68.3% for the placebo group.

Dr. Boyer reported that based on the observed efficacy and safety, the external data monitoring committee recommended that the study be stopped due to futility and that participants discontinue both ipilimumab and placebo.

"As a consequence of the results of this study, monotherapy with pembrolizumab remains a standard of care for this population of patients. Despite the benefits of this type of treatment, almost 50% of these patients die of their disease within two years, so future research will focus on other ways to improve outcomes," he reported.
-end-
About the IASLC:

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 8,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit http://www.iaslc.org for more information.

About the WCLC:

The WCLC is the world's largest meeting dedicated to lung cancer and other thoracic malignancies, attracting nearly 7,500 researchers, physicians and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit wclc2020.iaslc.org.

International Association for the Study of Lung Cancer

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.